News

All of our latest updates

Press releases

News

December 12, 2025
Angelica Loskog, CEO/CSO at Lokon, was an invited speaker to discuss armed oncolytic viruses for pancreatic cancer in a Horizon session at the ESMO-IO meeting in London.
September 13, 2024
Gustav Ullenhag, principal investigator of the LOKON003 trial presented the study at ESMO in Barcelona. In this study, LOAd703 TME gene engineering was used for patients with malignant melanoma in combination with PD-1/PD-L1 blockade.
September 13, 2024
Angelica Loskog, the CEO/CSO at Lokon presented data from the LOKON002 trial at ESMO. In this study, LOAd703 TME gene engineering was combined with chemotherapy in solid malignancies.

Media

Malou efter 10
Bengt fick aggressiv cancer - hade ett år kvar att leva
Barncancerfonden
Immunterapi på 100 sekunder
Malou efter 10
Forskarna om cancervaccinet: ”Behövs pengar”
Uppsala universitet
Immunterapi är ett nytt sätt att bekämpa cancer.
Forskarpodden
Virus som dödar cancer